Novo Nordisk(US:NVO) GLP1减重宝典·2025-07-31 09:21Core Viewpoint - The Danish pharmaceutical giant Novo Nordisk has lowered its full-year sales and profit forecasts due to slowing growth of its key drugs in the U.S. market, particularly Wegovy and Ozempic, amid increased competition and regulatory challenges [2][4]. Group 1: Sales and Profit Forecasts - The company now expects sales growth for the year to be between 8% and 14% on a constant currency basis, down from the previous forecast of 13% to 21% [2]. - Operating profit growth expectations have been revised from 16% to 24% down to 10% to 16% [2]. Group 2: Market Challenges - The downward adjustment in sales expectations for Wegovy in the U.S. is attributed to the widespread use of mixed formulations of semaglutide and slower-than-expected market expansion, along with intensified competition [4]. - The company faces challenges in the U.S. Wegovy market, particularly due to increased competition from mixed formulations of semaglutide that have gained popularity following FDA rulings on drug shortages [4]. Group 3: Regulatory and Safety Concerns - Despite the FDA's set deadline for large-scale compounded drugs ending on May 22, 2025, illegal and unsafe compounded medications remain prevalent in the market, posing significant health risks to patients [4][5]. - Novo Nordisk is actively pursuing legal actions to protect patients from counterfeit drugs and has expressed high concern over the ongoing circulation of unregulated GLP-1 compounds [5]. Group 4: Future Outlook - The company previously indicated that with increased regulatory enforcement, the supply of these generic drugs is expected to gradually decrease in the second half of the year, potentially alleviating competitive pressure [6]. - Disappointing clinical trial results, particularly for the new obesity treatment candidate CagriSema, have further weakened market expectations for the growth of its obesity treatment product line [8].